Alpha Tau Medical LTD.

Montreal, Quebec

Oncologysmall moleculePhase IListed · DRTS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

4mo agoTrial registeredFeb 20, 2026Source filing (opens the source filing in a new tab)

Momentum

71no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
U01 · $1.8M · non-dilutive
Apr 16, 2024
UNIVERSITY OF FLORIDA · PI MILLER, COURTNEY A · NIMH · award ends Jan 31, 2029 · Preclinical development of a precision therapy for a monogenic mental health disorder
NIH RePORTER · NIH RePORTER 11075913 (opens the source filing in a new tab)
Trial
EARLY_PHASE1 registered
Dec 15, 2023
Bacterial Vaginosis, Vulvovaginal Candidiasis · RECRUITING · sponsor: Queen's Medical Center · Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
ClinicalTrials.gov · NCT05753813 (opens the source filing in a new tab)
Grant
R03 · $89k · non-dilutive
Apr 1, 2023
VIRGINIA COMMONWEALTH UNIVERSITY · PI MILLER, CARRIE A. · NCI · award ends Jul 31, 2026 · Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults
NIH RePORTER · NIH RePORTER 10813769 (opens the source filing in a new tab)
Grant
R01 · $678k · non-dilutive
Sep 1, 2022
UNIVERSITY OF FLORIDA · PI RUMBAUGH, GAVIN R · NIMH · award ends Jun 30, 2027 · Neurodevelopmental Disorder Risk Gene Regulation of Intrinsic Membrane Excitability: A Rheostat that Tunes Dendritic Morphogenesis to Regulate Circuit Assembly During Development
NIH RePORTER · NIH RePORTER 11140431 (opens the source filing in a new tab)
Trial
NA registered
Oct 20, 2020
Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma · ACTIVE_NOT_RECRUITING · sponsor: Alpha Tau Medical LTD. · Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
ClinicalTrials.gov · NCT04002479 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator MILLER, CARRIE A. is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.27same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
7mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Neurodevelopmental Disorder Risk Gene Regulation of Intrinsic Membrane Excitability: A Rheostat that Tunes Dendritic Morphogenesis to Regulate Circuit Assembly During Development
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH U01 · $1.8M · Preclinical development of a precision therapy for a monogenic mental health disorder
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R03 · $0.1M · Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults
Jan 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

U01 · $1.8M · non-dilutive

EARLY_PHASE1 registered

R03 · $89k · non-dilutive

R01 · $678k · non-dilutive

NA registered